Combined analysis of the phase III studies with palonosetron in the prevention of emesis from moderately emetogenic chemotherapy;Analisi congiunta degli studi di fase III con palonosetron nella prevenzione dell'emesi da chemioterapia moderatamente emetogena

Tumori

Volumn 94, Issue 2, 2008, Pages 14-22

  Di Maio, Massimo ^a   Gallo, Ciro ^b   Perrone, Francesco ^c  

^a Presidio Ospedaliero 'N Giannettasio'   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOLASETRON MESILATE; DOXORUBICIN; EPIRUBICIN; GRANISETRON; IDARUBICIN; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; MITOXANTRONE; ONDANSETRON; PALONOSETRON; SEROTONIN 3 ANTAGONIST; TROPISETRON;

CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; NAUSEA AND VOMITING;

ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III AS TOPIC; GRANISETRON; HUMANS; INDOLES; ISOQUINOLINES; MORPHOLINES; ONDANSETRON; QUINOLIZINES; QUINUCLIDINES; RESEARCH DESIGN; SEROTONIN ANTAGONISTS; TREATMENT OUTCOME; VOMITING;

EID: 45249111770     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (16)

1. Kris MG, Hesketh PJ, Somerfield MR et al: American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006; 24: 2932-2947. Erratum in: J Clin Oncol 2006; 24: 5341-5342.
2. Italian Group for Antiemetic Research: Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide. J Clin Oncol 2004; 22: 725-729.
3. Warr D, Bramwell V, Anderson D, Charette M, and the Systemic Treatment Disease Site Group: Use of 5-HT3 receptor antagonists in patient receiving moderately or highly emetogenic chemotherapy Curr Oncol 2001; 8: 69-82. (Versione aggiornata: Cancer Care Ontario: Use of 5-HT3 receptor antagonists in patients receiving moderately or highly emetogenic chemotherapy, http://www.cancercare.on.ca/pdf/pebc12_3f.pdf)
4. Peterson K, McDonagh MS, Carson S et al: Drug class review on newer antiemetics, final report, http://www.ohsu.edu/drugeffectiveness/reports/ documents/Antiemetics%20Final%20Report.pdf
5. Del Giglio A, Soares HP, Caparroz C et al: Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting. Cancer 2000; 89: 2301-2308.
6. Jordan K, Hinke A, Grothey A et al: Granisetron versus tropisetron for prophylaxis of acute chemotherapy-induced emesis: a pooled analysis. Support Care Cancer 2005; 13: 26-31.
7. Jordan K, Hinke A, Grothey A et al: A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer 2007; 15: 1023-1033. Epub 2007 Jan 5.
8. Thompson SG: Meta-analysis of clinical trials, in Encyclopedia of Biostatistics, 1998.
9. Gralla R, Lichinitser M, Van der Vegt S et al: Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003; 14: 1570-1577.
10. Eisenberg P, Figueroa-Vadillo J, Zamora R et al: Improved prevention of moderate emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003; 98: 2473-2482.
11. Aapro MS, Grunberg SM, Manikhas GM et al: A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006; 17: 1441-1449.
12. The European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products: Points to consider on switching between superiority and non inferiority. London, 27 July 2000.
13. Rubenstein EB, Gralla RJ, Eisenberg P et al: Palonosetron compared with ondansetron or dolasetron for prevention of acute & delayed chemotherapy-induced nausea and vomiting: combined results of two phase III trials. Proc ASCO 2003; abstr 2932.
14. Hajdenberg J, Grote T, Yee L et al: Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting. J Support Oncol 2006; 4: 467-471.
15. Oo TH, Hesketh PJ: Drug insight: new antiemetics in the management of chemotherapy-induced nausea and vomiting. Nat Clin Pract Oncol 2005; 2: 196-201.
16. Grote T, Hajdenberg J, Cartmell A et al: Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. J Support Oncol 2006; 4: 403-408.